Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
  • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
  • A61K51/04—Organic compounds
  • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
  • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
  • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
  • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
  • A61K51/04—Organic compounds
  • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
  • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
  • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
  • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
  • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
  • A61K51/04—Organic compounds
  • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
  • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
  • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Physics & Mathematics (AREA)
• Optics & Photonics (AREA)
• Immunology (AREA)
• Oncology (AREA)
• Cell Biology (AREA)
• Dermatology (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Dispersion Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Nanotechnology (AREA)
• Extraction Or Liquid Replacement (AREA)
• Saccharide Compounds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=48805787

Family Applications (1)

Country Status (36)

Families Citing this family (4)

Family Cites Families (5)

• 2013
  • 2013-06-05 GB GBGB1310028.4A patent/GB201310028D0/en not_active Ceased
• 2014
  • 2014-06-05 AP AP2015008894A patent/AP2015008894A0/xx unknown
  • 2014-06-05 US US14/896,424 patent/US20160114063A1/en not_active Abandoned
  • 2014-06-05 RS RS20200349A patent/RS60091B1/sr unknown
  • 2014-06-05 CA CA2914278A patent/CA2914278C/en active Active
  • 2014-06-05 KR KR1020157036893A patent/KR102321763B1/ko active IP Right Grant
  • 2014-06-05 EA EA201501174A patent/EA201501174A1/ru unknown
  • 2014-06-05 CU CU2015000174A patent/CU24535B1/es unknown
  • 2014-06-05 ES ES14728571T patent/ES2782624T3/es active Active
  • 2014-06-05 SI SI201431535T patent/SI3003401T1/sl unknown
  • 2014-06-05 CN CN201480044621.8A patent/CN105592863B/zh active Active
  • 2014-06-05 UA UAA201512920A patent/UA120352C2/uk unknown
  • 2014-06-05 TN TN2015000527A patent/TN2015000527A1/en unknown
  • 2014-06-05 EP EP14728571.2A patent/EP3003401B1/en active Active
  • 2014-06-05 BR BR112015030298A patent/BR112015030298A2/pt active Search and Examination
  • 2014-06-05 LT LTEP14728571.2T patent/LT3003401T/lt unknown
  • 2014-06-05 WO PCT/EP2014/061743 patent/WO2014195423A1/en active Application Filing
  • 2014-06-05 DK DK14728571.2T patent/DK3003401T3/da active
  • 2014-06-05 PT PT147285712T patent/PT3003401T/pt unknown
  • 2014-06-05 MA MA38650A patent/MA38650B1/fr unknown
  • 2014-06-05 MX MX2015016726A patent/MX366028B/es active IP Right Grant
  • 2014-06-05 MY MYPI2015704399A patent/MY180717A/en unknown
  • 2014-06-05 PL PL14728571T patent/PL3003401T3/pl unknown
  • 2014-06-05 JP JP2016517608A patent/JP6580559B2/ja not_active Expired - Fee Related
  • 2014-06-05 SG SG11201509856RA patent/SG11201509856RA/en unknown
  • 2014-06-05 AU AU2014276885A patent/AU2014276885B2/en not_active Ceased
  • 2014-06-05 PE PE2015002566A patent/PE20160215A1/es unknown
• 2015
  • 2015-11-22 IL IL242704A patent/IL242704B/en active IP Right Grant
  • 2015-12-03 SA SA515370233A patent/SA515370233B1/ar unknown
  • 2015-12-04 PH PH12015502715A patent/PH12015502715A1/en unknown
  • 2015-12-04 DO DO2015000294A patent/DOP2015000294A/es unknown
  • 2015-12-04 NI NI201500173A patent/NI201500173A/es unknown
  • 2015-12-04 CL CL2015003554A patent/CL2015003554A1/es unknown
  • 2015-12-04 CR CR20150642A patent/CR20150642A/es unknown
• 2016
  • 2016-01-04 ZA ZA2016/00027A patent/ZA201600027B/en unknown
• 2020
  • 2020-03-19 HR HRP20200456TT patent/HRP20200456T1/hr unknown
• 2021
  • 2021-05-04 US US17/307,857 patent/US20220023449A1/en not_active Abandoned

Also Published As

Similar Documents